Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter October 9, 2013

Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia

  • Shang-Jyh Kao , Chun-Yi Chuang , Chih-Hsin Tang , Chien-Huang Lin , Mauo-Ying Bien , Ming-Chih Yu , Kuan-Jen Bai , Shun-Fa Yang EMAIL logo and Ming-Hsien Chien EMAIL logo

Abstract

Background: Endothelial cell-specific molecule (ESM)-1 is a soluble proteoglycan expressed by the vascular endothelium and which also circulates in the bloodstream. Inflammatory cytokines and proangiogenic growth factors increase its expression, and increased serum levels are found in immunocompetent patients with sepsis. The aim of this study was to investigate differential changes in plasma levels of ESM-1 before and after antibiotic treatment in hospitalized adult patients with community-acquired pneumonia (CAP).

Methods: Plasma ESM-1 levels were measured in 82 adult patients with CAP and 82 healthy controls using a commercial enzyme-linked immunosorbent assay (ELISA). Upon initial hospitalization, Acute Physiology and Chronic Health Evaluation II (APACHE II), CURB-65, and Pneumonia Severity Index (PSI) scores were determined to assess CAP severity in these patients.

Results: Results showed a decline in the number of white blood cells (WBCs) and neutrophils, and decreases in the concentrations of C-reactive protein (CRP) and ESM-1 after antibiotic treatment. The plasma concentration of ESM-1, but not CRP or the WBC count, was correlated with the severity of CAP based on the PSI (r=0.554, p<0.001), CURB-65 (r=0.510, p<0.001), and APACHE II scores (r=0.447, p<0.001).

Conclusions: Plasma levels of ESM-1 may be able to play a role in the diagnosis and clinical assessment of the severity of CAP, which could potentially guide the development of treatment strategies.


Corresponding authors: Shun-Fa Yang, PhD and Ming-Hsien Chien, PhD, Graduate Institute of Clinical Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei 110, Taiwan, Phone: +886 2 27361661 ext. 3237, Fax: +886 2 27390500, E-mail: ;

This study was supported by a grant (SKH-TMU-102-04) from Shin Kong Wu Ho-Su Memorial Hospital.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research funding played no role in thestudy design; in the collection, analysis, and interpretationof data; in the writing of the report; or in the decision tosubmit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

1. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004;32:234–8.10.1007/s15010-004-3107-zSearch in Google Scholar PubMed

2. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl 3):iii3–9.10.1093/jac/dkr094Search in Google Scholar PubMed PubMed Central

3. Lee YT, Chen SC, Shyu LY, Lee MC, Wu TC, Tsao SM, et al. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin Chim Acta 2012;413:630–5.10.1016/j.cca.2011.12.010Search in Google Scholar PubMed

4. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637–44.10.1001/archinte.164.6.637Search in Google Scholar PubMed

5. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865–9.10.1378/chest.07-0164Search in Google Scholar PubMed

6. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect 2011;17(Suppl 6): E1–59.10.1111/j.1469-0691.2011.03672.xSearch in Google Scholar PubMed PubMed Central

7. Almirall J, Bolibar I, Toran P, Pera G, Boquet X, Balanzo X, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest 2004;125:1335–42.10.1378/chest.125.4.1335Search in Google Scholar PubMed

8. Holm A, Nexoe J, Bistrup LA, Pedersen SS, Obel N, Nielsen LP, et al. Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract 2007;57:547–54.Search in Google Scholar

9. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458–64.10.1074/jbc.271.34.20458Search in Google Scholar PubMed

10. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417–25.10.1159/000025758Search in Google Scholar PubMed

11. Wellner M, Herse F, Janke J, Gorzelniak K, Engeli S, Bechart D, et al. Endothelial cell specific molecule-1 – a newly identified protein in adipocytes. Horm Metab Res 2003;35:217–21.10.1055/s-2003-39477Search in Google Scholar PubMed

12. Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099–106.10.4049/jimmunol.167.6.3099Search in Google Scholar PubMed

13. Scherpereel A, Gentina T, Grigoriu B, Senechal S, Janin A, Tsicopoulos A, et al. Overexpression of endocan induces tumor formation. Cancer Res 2003;63:6084–9.Search in Google Scholar

14. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006;34:532–7.10.1097/01.CCM.0000198525.82124.74Search in Google Scholar PubMed

15. Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, et al. Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 2012;27:522 e511–27.10.1016/j.jcrc.2011.07.077Search in Google Scholar PubMed PubMed Central

16. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27–72.10.1086/511159Search in Google Scholar PubMed PubMed Central

17. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336: 243–50.10.1056/NEJM199701233360402Search in Google Scholar PubMed

18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818–29.10.1097/00003246-198510000-00009Search in Google Scholar

19. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377–82.10.1136/thorax.58.5.377Search in Google Scholar PubMed PubMed Central

20. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219–25.10.1016/j.amjmed.2007.10.033Search in Google Scholar PubMed

21. Jeong KY, Kim K, Kim TY, Lee CC, Jo SO, Rhee JE, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J 2011;28:122–7.10.1136/emj.2009.089383Search in Google Scholar PubMed

22. Torres A, Ramirez P, Montull B, Menéndez R. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012;33:266–71.10.1055/s-0032-1315638Search in Google Scholar PubMed

23. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396–402.10.1164/ajrccm.164.3.2009052Search in Google Scholar PubMed

24. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009;64(Suppl 3):iii1–55.10.1136/thx.2009.121434Search in Google Scholar PubMed

25. Arnold FW, Brock GN, Peyrani P, Rodriguez EL, Diaz AA, Rossi P, et al. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-acquired pneumonia organization (CAPO) international cohort study. Respir Med 2010;104:1736–43.10.1016/j.rmed.2010.05.022Search in Google Scholar PubMed

26. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:10.10.1186/1471-2334-7-10Search in Google Scholar PubMed PubMed Central

27. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 2006;27:9–11.10.1183/09031936.06.00130305Search in Google Scholar PubMed

28. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: a review. QJM 2009;102: 379–88.10.1093/qjmed/hcp027Search in Google Scholar PubMed

29. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003;21:939–43.10.1183/09031936.03.00055103Search in Google Scholar PubMed

30. Tateda K, Kusano E, Matsumoto T, Kimura K, Uchida K, Nakata K, et al. Semi-quantitative analysis of Streptococcus pneumoniae urinary antigen: kinetics of antigen titers and severity of diseases. Scand J Infect Dis 2006;38:166–71.10.1080/00365540500400944Search in Google Scholar PubMed

31. Hatfield KJ, Lassalle P, Leiva RA, Lindas R, Wendelboe O, Bruserud O. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology 2011;16:351–6.10.1179/102453311X13127324303434Search in Google Scholar PubMed

32. Kruger S, Welte T. Biomarkers in community-acquired pneumonia. Expert Rev Respir Med 2012;6:203–14.10.1586/ers.12.6Search in Google Scholar PubMed

Received: 2013-08-09
Accepted: 2013-08-28
Published Online: 2013-10-09
Published in Print: 2014-03-01

©2014 by Walter de Gruyter Berlin Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/cclm-2013-0638/pdf
Scroll to top button